4/4
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4
12:16 pm
arqt
BIZCLIK MEDIA PUBLISHES APRIL EDITION OF HEALTHCARE DIGITAL [Yahoo! Finance]
Low
Report
BIZCLIK MEDIA PUBLISHES APRIL EDITION OF HEALTHCARE DIGITAL [Yahoo! Finance]
4/4
12:16 pm
arqt
BizClik Media Launches April Editions of Technology, Data Centre & Mobile Magazines [Yahoo! Finance]
Low
Report
BizClik Media Launches April Editions of Technology, Data Centre & Mobile Magazines [Yahoo! Finance]
4/4
05:56 am
arqt
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? [Yahoo! Finance]
Medium
Report
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? [Yahoo! Finance]
4/3
10:46 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
4/3
08:04 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
4/3
08:03 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
4/2
01:16 pm
arqt
Arcutis and Padagis Agree to Stay Patent Lawsuit
Medium
Report
Arcutis and Padagis Agree to Stay Patent Lawsuit
3/27
08:00 am
arqt
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
Low
Report
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
3/17
07:07 am
arqt
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]
High
Report
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]
3/11
03:17 pm
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
3/7
08:00 am
arqt
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Low
Report
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
3/6
07:08 pm
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]
3/5
07:07 pm
arqt
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
3/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
10:53 am
arqt
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Medium
Report
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting [Yahoo! Finance]
2/28
09:00 am
arqt
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Medium
Report
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
2/27
11:43 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $15.00. They now have a "neutral" rating on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $15.00. They now have a "neutral" rating on the stock.
2/26
12:28 pm
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
2/26
11:36 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $20.00 to $21.00. They now have an "outperform" rating on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $20.00 to $21.00. They now have an "outperform" rating on the stock.
2/26
08:00 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
2/26
08:00 am
arqt
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Low
Report
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
2/26
02:27 am
arqt
Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/25
04:00 pm
arqt
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/24
10:19 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.